Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-09-13), Dipna Pharmachem's 5-Day RSI is 20.90.
The industry rank for Dipna Pharmachem's 5-Day RSI or its related term are showing as below:
BOM:543594's 5-Day RSI is ranked better than 86.17% of 694
companies
in the Healthcare Providers & Services industry
Industry Median: 42.7
vs BOM:543594: 20.90
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Dipna Pharmachem 5-Day RSI Related Terms
Dipna Pharmachem 5-Day RSI Competitor Comparison
For the Pharmaceutical Retailers subindustry, Dipna Pharmachem's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dipna Pharmachem 5-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dipna Pharmachem's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Dipna Pharmachem's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dipna Pharmachem (BOM:543594) has a 5-Day RSI of 20.90 as of Sep. 13, 2026. According to the industry distribution chart, Dipna Pharmachem ranks #96 out of 694 companies in the Healthcare Providers & Services industry, placing it in the top 13.8%.
Is Dipna Pharmachem's 5-Day RSI too high?
Dipna Pharmachem's current 5-Day RSI is 20.90. The Healthcare Providers & Services industry median 5-Day RSI is 42.70. Dipna Pharmachem's value of 20.90 is 51.1% below this industry median. Based on the distribution chart, Dipna Pharmachem ranks #96 out of 694 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Dipna Pharmachem has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dipna Pharmachem's 5-Day RSI compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dipna Pharmachem ranks #96 out of 694 companies for 5-Day RSI. This places Dipna Pharmachem in the top 14% of its industry — outperforming the majority of peers. The industry median 5-Day RSI is 42.70. Dipna Pharmachem's value of 20.90 is 51.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Healthcare Providers & Services company?
The median 5-Day RSI among Healthcare Providers & Services companies is 42.70, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dipna Pharmachem's current 5-Day RSI of 20.90 is 51.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 5-Day RSI is 42.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dipna Pharmachem's current 5-Day RSI is 20.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dipna Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Dipna Pharmachem (BOM:543594) is currently considered Possible Value Trap. The stock's GF Value™ is ₹8.88, compared to a current price of ₹4.56 — trading 48.6% below its estimated fair value. The current 5-Day RSI is 20.90 and 51.1% below the Healthcare Providers & Services industry median of 42.70. Dipna Pharmachem's overall GF Score™ is 63/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Dipna Pharmachem (BOM:543594), the current 5-Day RSI is 20.90 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dipna Pharmachem (BOM:543594) Overvalued in 2026?
Based on GuruFocus' analysis, Dipna Pharmachem stock appears to be undervalued.
The current stock price of ₹4.56 is trading 48.6% below its estimated GF Value™ of ₹8.88.
GuruFocus considers Dipna Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:543594:
5-Day RSI: 20.90
GF Value™: ₹8.88 vs. price of ₹4.56 (48.6% below fair value)
Industry Position: 51.1% below the Healthcare Providers & Services median (#96 of 694)
No single metric tells the full story. See the BOM:543594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dipna Pharmachem Ltd is engaged in the trading and distribution of a wide range of pharmaceutical raw materials which is also known as APIs (Active Pharmaceutical Ingredients), Excipient and chemical formulation products. The company's product portfolio comprises of Hydrocortisone Acetate, Aceclofenac, Asprin, Levofloxacin, and others.
63GF Score
Get the complete analysis for BOM:543594
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543594 has been successfully added to your 
